```
<!--StartFragment-->
RESULT 8
ID
     AAA15967 standard; cDNA; 2054 BP.
XX
AC
     AAA15967;
XX
DT
     12-JUN-2000 (first entry)
XX
DΕ
     Human protein clone HP02419 full length coding sequence.
XX
KW
     Human protein; hydrophobic domain; nutritional source; haematopoiesis;
KW
     cytokine production; cell proliferation; cell differentiation;
KW
     immune deficiency; infectious disease; autoimmune disorder; asthma;
KW
     multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
KW
     allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
KW
     nervous system disorder; Alzheimer's disease; Parkinson's disease;
     Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
KW
KW
     systemic cytokine damage; tissue differentiation; contraceptive; stroke;
KW
     coagulation disorder; myocardial infarction; inflammatory condition;
KW
     septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
KW
     nephritis; therapy; ss.
XX
OS
     Homo sapiens.
XX
PN
     WO200005367-A2.
XX
PD
     03-FEB-2000.
XX
PF
     22-JUL-1999;
                    99WO-JP003929.
XX
PR
     24-JUL-1998;
                    98JP-00208820.
PR
     07-AUG-1998;
                    98JP-00224105.
PR
     25-AUG-1998;
                    98JP-00238116.
PR
     09-SEP-1998;
                    98JP-00254736.
PR
     29-SEP-1998;
                    98JP-00275505.
XX
PA
     (SAGA ) SAGAMI CHEM RES CENT.
     (PROT-) PROTEGENE INC.
PA
XX
PΙ
     Kato S,
             Kimura T;
XX
DR
     WPI; 2000-182694/16.
DR
     P-PSDB; AAY94879.
XX
PT
     Novel human proteins having hydrophobic domains useful for treating
PT
     osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
PT
     sclerosis, rheumatoid arthritis, cancer; anemia, and stroke.
XX
PS
     Claim 4; Page 294-296; 351pp; English.
XX
CC
     This sequence encodes a human protein of the invention, which has
CC
     hydrophobic domains. The DNA sequences can be used as a probe or as a
CC
     genetic marker. The protein can also be used as a marker, and to identify
CC
     potential genetic disorders. The DNA and protein can also be used as
CC
     nutritional sources or supplements. The protein exhibits cytokine, cell
CC
     proliferation, cell differentiation activities and induces production of
CC
     other cytokines in certain cell populations. The protein also exhibits
CC
     immune stimulating or immune suppressing activity. It can be used in the
CC
     treatment of various immune deficiencies and disorders, and to treat
CC
     infectious diseases caused by viral, bacterial, fungal or other
```

```
CC
   infections. The protein is also used for treating autoimmune disorders
CC
   such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
   arthritis. It is also useful in the treatment of allergic reactions and
CC
CC
   conditions such as asthma, and in immune suppression after organ
CC
   transplantation. The protein is useful in regulation of haematopoiesis
CC
   and consequently in the treatment of myeloid or lymphoid cell
CC
   deficiencies. It is also used in compositions for tissue growth or
CC
   regeneration. The protein is also used in the treatment of osteoporosis
CC
   or osteoarthritis and in the treatment of periodontal disease and other
CC
   tooth repair processes. The protein is used in the treatment of nervous
CC
   system disorders such as Alzheimer's disease, Parkinson's disease, and
CC
   Huntington's disease. They are useful for protection or regeneration and
   treatment of lung or liver fibrosis, reperfusion injury in various
CC
CC.
   tissues, and conditions resulting from systemic cytokine damage. They are
CC
   also used for promoting or inhibiting tissue differentiation. They are
CC
   also used as contraceptives since they exhibit activin or inhibin related
CC
   activities and as a fertility inducing therapeutic. They are used for
   treating various coagulation disorders and in treatment and prevention of
CC
CC
   conditions resulting from coagulation activities e.g. myocardial
CC
   infarction or stroke. They also acts as receptors, receptor ligands or
CC
   inhibitors or agonists of receptor/ligand interactions. They are used to
CC
   treat inflammatory conditions such as septic shock, sepsis, ischaemia
CC
   reperfusion injury, arthritis, and nephritis. They can be used to prevent
CC
   tumours
XX
   Sequence 2054 BP; 470 A; 489 C; 484 G; 611 T; 0 U; 0 Other;
SQ
 Query Match
                   97.6%; Score 930.8; DB 3; Length 2054;
 Best Local Similarity
                   99.8%; Pred. No. 1.3e-214;
 Matches 932; Conservative
                        0; Mismatches
                                        Indels
        21 CACATGGCCGAGTCCGCCCCCCCCCCCCGCCGCCGCTGCAGCCGTCGCCTTCGG 80
Qy
          Db
        Qy
          Db
        Qу
           Db
       Qу
          Db
       261 TGCGCCCGGAGCGATGAAGATGGTCGCGCCCTGGACGCGGTTCTACTCCAACAGCTGCTG 320
Qу
          Db
       241 TGCGCCCGGAGCGATGAAGATGGTCGCGCCCTGGACGCGGTTCTACTCCAACAGCTGCTG 300
       321 CTTGTGCTGCCATGTCCGCACCGGCACCATCCTGCTCGGCGTCTGGTATCTGATCATCAA 380
Qу
           Db
       301 CTTGTGCTGCCATGTCCGCACCGGCACCATCCTGCTCGGCGTCTGGTATCTGATCATCAA 360
       381 TGCTGTGGTACTGTTGATTTTATTGAGTGCCCTGGCTGATCCGGATCAGTATAACTTTTC 440
Qy
          Db
       361 TGCTGTGGTACTGTTGATTTTATTGAGTGCCCTGGCTGATCCGGATCAGTATAACTTTTC 420
       441 AAGTTCTGAACTGGGAGGTGACTTTGAGTTCATGGATGATGCCAACATGTGCATTGCCAT 500
Qy
```

Db	421	AAGTTCTGAACTGGGAGGTGACTTTGAGTTCATGGATGATGCCAACATGTGCCAT	480
Qy	501	TGCGATTTCTCTCATGATCCTGATATGTGCTATGGCTACTTACGGAGCGTACAAGCA	560
Db	481	TGCGATTTCTCTCTCATGATCCTGATATGTGCTATGGCTACTTACGGAGCGTACAAGCA	540
Qy	561	ACGCGCAGCCTGGATCATCCCATTCTTCTGTTACCAGATCTTTGACTTTGCCCTGAACAT	620
Db	541	ACGCGCAGCCTGGATCATCCCATTCTTCTGTTACCAGATCTTTGACTTTGCCCTGAACAT	600
Qy	621	GTTGGTTGCAATCACTGTGCTTATTTATCCAAACTCCATTCAGGAATACATAC	680
Db	601	GTTGGTTGCAATCACTGTGCTTATTTATCCAAACTCCATTCAGGAATACATAC	660
Qy	681	GCCTCCTAATTTTCCCTACAGAGATGATGTCATGTCAGTGAATCCTACCTGTTTGGTCCT	740
Db	661		720
Qy .	741	TATTATTCTTCTGTTTATTAGCATTATCTTGACTTTTAAGGGTTACTTGATTAGCTGTGT	800
Db	721	TATTATTCTTCTGTTTATTAGCATTATCTTGACTTTTAAGGGTTACTTGATŢAGCTGTGT	780
Qу	801	TTGGAACTGCTACCGATACATCAATGGTAGGAACTCCTCTGATGTCCTGGTTTATGTTAC	860
Db	781	TTGGAACTGCTACCGATACATCAATGGTAGGAACTCCTCTGATGTCCTGGTTTATGTTAC	840
Qy	861	CAGCAATGACACTACGGTGCTACCCCCGTATGATGATGCCACTGTGAATGGTGCTGC	920
Db	841		900
Qy	921	CAAGGAGCCACCTTACGTGTCTGCCTAA 954	
Db			
· ————————————————————————————————————			